Experimental pancreatic cancer pill daraxonrasib shows tumour shrinkage in trial

A daily pill called daraxonrasib appears to shrink tumours and may even eliminate them in some patients with pancreatic cancer, one of the deadliest forms of the disease. The findings come from a clinical trial, and the drug is being studied as a potential treatment option. Researchers have described the early results as a significant source of hope for patients facing this difficult diagnosis. The article does not provide further detail on trial size, timing, or regulatory status beyond these early observations.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.




Discussion (0)
Log in to join the discussion and vote.
Log in